Neuronetics (Neuronetics) Float Percentage Of Total Shares Outstanding

: 94.58% (As of Today)

View and export this data going back to 2018. Start your Free Trial

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neuronetics's float shares is 28.34 Mil. Neuronetics's total shares outstanding is 29.97 Mil. Neuronetics's float percentage of total shares outstanding is 94.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neuronetics's Insider Ownership is 13.93%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neuronetics's Institutional Ownership is 15.58%.

Neuronetics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Neuronetics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	28.34	/	29.97
	=	94.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuronetics (Neuronetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Executives

Keith J Sullivan	director, officer: President and CEO	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan	officer: Sr. VP, GC, CCO and Secretary	24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong	officer: CFO	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc	10 percent owner	245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper	director	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook	director	162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger	director	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper	officer: VP of Prod. Dev. & Operations	C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley	director	2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie	officer: Chief Commercial Officer	C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355